Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy

Figures & data

Table 1 Patients’ Clinicopathological Characteristics and Treatment Response

Variables		Value or N (%)
Sex	Female	23(25.27)
	Male	68 (74.73)
Age(years)	Mean ± Standard Deviation	59.15 ± 9.74
	Median (range)	61.00 (32.00–80.00)
Smoking history	No	32 (35.16)
	Yes	59 (64.84)
ECOG score	0–1	84 (92.31)
	2–3	7 (7.69)
Histology	Non-SCC	48 (56.04)
	SCC	40 (43.96)
T stage	T1–2	22 (24.18%)
	T3–4	69 (75.82%)
N stage	N0–1	16 (17.58%)
	N2–3	75 (82.42%)
TNM stage	III	24 (26.37)
	IV	67 (73.63)
Radiotherapy	No	77 (84.62)
	Yes	14 (15.38)
FAR	Mean ±Standard Deviation	0.14 ± 0.05
	Median (range)	0.13 (0.04–0.35)
Best response	CR	0 (0)
	PR	50 (54.95)
	SD	36 (39.56)
	PD	5 (5.49)

Abbreviations: ECOG score, Eastern Tumor Cooperation Group score; SCC, squamous cell carcinoma; Non-SCC, none squamous cell carcinoma; TNM, tumor, node, and metastases; FAR, fibrinogen-albumin ratio; CR, complete remission; PR, partial remission; SD, stable disease; PD, disease progression.

Table 2 Univariate and Multivariate Analyses for ORR in Patients with NSCLC

Variables	N (%)	Univariate Analysis	Multivariate Analysis
		OR (95% CI) P value	OR (95% CI) P value
Sex
Female	23 (25.27%)	1.0
Male	68 (74.73%)	1.47 (0.57, 3.79) 0.4285
Age(years)
<60	40 (43.96%)	1.0
≥60	51 (56.04%)	1.71 (0.74, 3.96) 0.2076
Smoking history
No	32 (35.16%)	1.0
Yes	59 (64.84%)	1.65 (0.69, 3.93) 0.2561
ECOG score
0–1	84 (92.31%)	1.0
2–3	7 (7.69%)	0.59 (0.12, 2.80) 0.5073
Histology
Non-SCC	51 (56.04%)	1.0
SCC	40 (43.96%)	1.73 (0.75, 4.03) 0.2011
T stage
T1-2	22 (24.18%)	1.0
T3-4	69 (75.82%)	0.80 (0.30, 2.12) 0.6539
N stage
N0–1	16 (17.58%)	1.0	17.45 (3.78, 80.54) 0.0002
N2–3	75 (82.42%)	7.27 (1.91, 27.77) 0.0037
TNM stage
III	24 (26.37%)	1.0
IV	67 (73.63%)	0.30 (0.11, 0.86) 0.0253	0.40 (0.10, 1.67) 0.2091
Radiotherapy
No	77 (84.62%)	1.0
Yes	14 (15.38%)	0.40 (0.12, 1.29) 0.1240
FAR
<0.175	71 (78.02%)	1.0
≥0.175	20 (21.98%)	0.19 (0.06, 0.59) 0.0040	0.10 (0.03, 0.36) 0.0005

Abbreviations: ORR, objective response rate; NSCLC, non-small cell lung cancer; ECOG score, Eastern Tumor Cooperation Group score; SCC, squamous cell carcinoma; Non-SCC, none squamous cell carcinoma; TNM, tumor, node, and metastases; FAR, fibrinogen-albumin ratio.

Figure 1 Kaplan–Meier survival curves for PFS stratified by different values of FAR.

Abbreviations: PFS, progression-free survival; FAR, fibrinogen-albumin ratio.

Figure 2 Kaplan–Meier survival curves for OS stratified by different values of FAR.

Abbreviations: OS, overall survival; FAR, fibrinogen-albumin ratio.

Table 3 Univariate and Multivariate Analyses for PFS in Patients with NSCLC

Variables	N (%)	Univariate Analysis	Multivariate Analysis
		HR (95% CI) P value	HR (95% CI) P value
Sex
Female	23 (25.27%)	1.0
Male	68 (74.73%)	0.61 (0.31, 1.19) 0.1494
Age(years)
<60	40 (43.96%)	1.0
≥60	51 (56.04%)	0.89 (0.47, 1.68) 0.7123
Smoking history
No	32 (35.16%)	1.0
Yes	59 (64.84%)	0.86 (0.45, 1.64) 0.6511
ECOG score
0–1	84 (92.31%)	1.0
2–3	7 (7.69%)	2.12 (0.88, 5.12) 0.0937
Histology
Non-SCC	51 (56.04%)	1.0
SCC	40 (43.96%)	1.11 (0.59, 2.09) 0.7460
T stage
T1-2	22 (24.18%)	1.0
T3-4	69 (75.82%)	2.10 (0.87, 5.03) 0.0971
N stage
N0-1	16 (17.58%)	1.0
N2-3	75 (82.42%)	0.95 (0.42, 2.15) 0.8970
TNM stage
III	24 (26.37%)	1.0
IV	67 (73.63%)	1.58 (0.72, 3.45) 0.2502
Radiotherapy
No	77 (84.62%)	1.0
Yes	14 (15.38%)	2.03 (0.98, 4.22) 0.0565
FAR
<0.145	57 (62.64%)	1.0
≥0.145	34 (37.36%)	2.60 (1.36, 4.98) 0.0038	2.68 (1.33, 5.43) 0.0061

Abbreviations: PFS, progression-free survival; NSCLC, non-small cell lung cancer; ECOG score, Eastern Tumor Cooperation Group score; SCC, squamous cell carcinoma; Non-SCC, none squamous cell carcinoma; TNM, tumor, node, and metastases; FAR, fibrinogen-albumin ratio.

Table 4 Univariate and Multivariate Analyses for OS in Patients with NSCLC

Variables	N (%)	Univariate Analysis	Multivariate Analysis
		HR (95% CI) P value	HR (95% CI) P value
Sex
Female	23 (25.27%)	1.0
Male	68 (74.73%)	1.12 (0.45, 2.81) 0.8056
Age (years)
<60	40 (43.96%)	1.0
≥60	51 (56.04%)	0.84 (0.39, 1.81) 0.6506
Smoking history
No	32 (35.16%)	1.0
Yes	59 (64.84%)	1.01 (0.43, 2.33) 0.9901
ECOG score
0-1	84 (92.31%)	1.0
2-3	7 (7.69%)	2.37 (0.94, 5.99) 0.0687
T stage
1-2	22 (24.18%)	1.0
3-4	69 (75.82%)	1.04 (0.42, 2.62) 0.9275
N stage
0-1	16 (17.58%)	1.0
2-3	75 (82.42%)	0.96 (0.36, 2.57) 0.9316
TNM stage
III	24 (26.37%)	1.0
IV	67 (73.63%)	1.25 (0.50, 3.12) 0.6352
Histology
Non-SCC	51 (56.04%)	1.0
SCC	40 (43.96%)	0.65 (0.30, 1.42) 0.2826
Radiotherapy
No	77 (84.62%)	1.0
Yes	14 (15.38%)	2.55 (1.11, 5.86) 0.0268	2.21 (0.83, 5.86) 0.1110
FAR
<0.145	57 (62.64%)	1.0
≥0.145	34 (37.36%)	3.74 (1.57, 8.90) 0.0028	4.95 (1.76, 13.89) 0.0024

Abbreviations: OS, overall survival; NSCLC, non-small cell lung cancer; ECOG score, Eastern Tumor Cooperation Group score; SCC, squamous cell carcinoma; Non-SCC, none squamous cell carcinoma; TNM, tumor, node, and metastases; FAR, fibrinogen-albumin ratio.